Clinical Trial Update: Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating high-dose melphalan with amifostine followed by autologous or syngeneic stem cell transplantation and maintenance therapy in p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Amifostine (amifostine)
• Melphalan (Melphalan)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Refractory Multiple Myeloma, Stage II Multiple Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2014-09-19